Rationale for design of biologically reversible drug derivatives: prodrugs.
D000042:Absorption; D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism; D001665:Binding Sites; D055598:Chemical Phenomena; D002621:Chemistry; D003692:Delayed-Action Preparations; D004798:Enzymes / Q000378:metabolism; D004950:Esterases / Q000378:metabolism; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006868:Hydrolysis; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007509:Irritants / Q000494:pharmacology; D009812:Odorants; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism; D012995:Solubility; D013329:Structure-Activity Relationship; D013429:Sulfatases / Q000378:metabolism; D013649:Taste
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004798:Enzymes; D007509:Irritants; D004364:Pharmaceutical Preparations; D004950:Esterases; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D013429:Sulfatases